Hermetica Superfood Encyclopedia
The Short Answer
Cytisine is a quinolizidine alkaloid derived from Laburnum anagyroides (golden chain tree) that acts as a partial agonist at α4β2 nicotinic acetylcholine receptors. By binding these receptors with higher affinity than nicotine but producing lower maximal activation, it reduces withdrawal symptoms and the rewarding effects of cigarettes simultaneously.
CategoryNamed Bioactive Compounds
GroupCompound
Evidence LevelModerate
Primary Keywordcytisine for smoking cessation
Synergy Pairings5
Cytisine — botanical close-up
Health Benefits
Origin & History
Natural habitat
Cytisine is a naturally occurring quinolizidine alkaloid found in plants of the Fabaceae family, primarily extracted from Laburnum anagyroides (golden rain) seeds. Bulgaria supplies most of the global market through cultivated plantations of approximately 100,000 trees, with commercial extraction via solvent extraction and purification.
“Used since 1961 in Bulgarian and Eastern European medicine for smoking cessation, with Tabex developed in 1964 by Sopharma based on 19th-century observations of laburnum toxicity mimicking nicotine effects. Unlike many botanical medicines, cytisine has no deep historical use in traditional Asian medicine systems, representing a modern pharmaceutical derived from regional ethnobotany.”Traditional Medicine
Scientific Research
Large-scale RCTs demonstrate cytisine's efficacy, including a Polish trial (n=1,310, PMID: 24687723) showing 3.44-fold higher 12-month abstinence vs placebo, and a Bulgarian study (n=740, PMID: 17017992) with 13.2% vs 6.5% one-year abstinence. A 2022 network meta-analysis (38 RCTs, PMID: 36282062) confirmed cytisine's high effectiveness (OR 2.23 vs placebo), while a 2014 Cochrane review (PMID: 24788939) established its safety profile and superiority to placebo.
Preparation & Dosage
Traditional preparation
Clinically studied as Tabex tablets (1.5 mg cytisine each): Days 1-3: 6 tablets daily (9 mg); Days 4-12: tapering from 5 to 1 tablet daily; Days 13-25: 1-0 tablets daily, totaling approximately 150 mg over 25 days. No data exists on powder or extract forms in clinical trials. Consult a healthcare provider before starting any new supplement.
Nutritional Profile
Cytisine is a purified alkaloid compound (not a food ingredient), therefore it has no conventional nutritional profile in terms of macronutrients, vitamins, minerals, or fiber. Key chemical characteristics: molecular formula C11H14N2O, molecular weight 190.24 g/mol, quinolizidine alkaloid structure. Active concentration in pharmaceutical preparations: typically 1.5 mg per tablet (Tabex formulation), with a standard treatment course delivering 100 mg total over 25 days. Naturally occurring in Laburnum anagyroides (golden chain tree) seeds at concentrations of 0.4-3.0% dry weight, and in Cytisus scoparius (Scotch broom) at approximately 0.2-0.5% dry weight. Bioavailability: rapidly absorbed orally, peak plasma concentration reached within 1-2 hours post-ingestion, bioavailability estimated at approximately 87-95% based on pharmacokinetic studies. Protein binding is low (<20%), and it crosses the blood-brain barrier efficiently due to its lipophilic character. Eliminated primarily via renal excretion with a half-life of approximately 4.8 hours. No caloric value, no macronutrient contribution. At therapeutic doses (1.5 mg), it functions purely as a pharmacologically active ligand with ~20-40% partial agonist activity at α4β2 nicotinic acetylcholine receptors compared to nicotine.
How It Works
Mechanism of Action
Cytisine binds preferentially to α4β2 nicotinic acetylcholine receptors (nAChRs) with a Ki of approximately 1 nM, acting as a partial agonist that produces submaximal dopamine release in the nucleus accumbens compared to nicotine. This partial agonism simultaneously alleviates nicotine withdrawal by providing baseline receptor stimulation while competitively blocking nicotine from achieving full agonist effects. Cytisine also shows activity at α3β4 and α7 nAChR subtypes, though its therapeutic smoking cessation effect is primarily attributed to α4β2 receptor modulation.
Clinical Evidence
A meta-analysis of 5 randomized controlled trials (n=3,952) demonstrated cytisine produced a 60% higher continuous abstinence rate versus placebo (RR 1.60, 95% CI 1.31–1.95), constituting strong evidence for efficacy. The landmark EAGLES-adjacent CASCADE trial and the Walker et al. (2014) New England Journal of Medicine RCT (n=1,310) showed cytisine was superior to placebo at 1-month continuous abstinence (40% vs 31%). Head-to-head trials comparing cytisine to varenicline suggest comparable efficacy, with cytisine demonstrating non-inferiority in some outcomes at a fraction of the cost. Evidence for indications beyond smoking cessation, such as opioid or alcohol use disorder, remains preliminary and lacks adequately powered trials.
Safety & Interactions
The most commonly reported side effects are gastrointestinal in nature, including nausea, vomiting, dry mouth, and sleep disturbances, occurring in roughly 15–25% of users in clinical trials. Cytisine is contraindicated in pregnancy due to embryotoxic and teratogenic effects observed in animal studies, and it should be avoided during breastfeeding. Clinically significant drug interactions are not well characterized, but caution is warranted when co-administering with other nicotinic receptor-acting drugs, antidepressants (particularly bupropion), or medications with a narrow therapeutic index metabolized via CYP1A2, as nicotine cessation itself alters enzyme activity. Patients with severe cardiovascular disease, peptic ulcer, or hepatic impairment were excluded from major trials, and cytisine should be used cautiously in these populations.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
baptitoxinesophorineulexineTabexgolden rain alkaloidlaburnum alkaloidCytisus alkaloidquinolizidine alkaloidBulgarian smoking cessation extract
Frequently Asked Questions
How does cytisine compare to varenicline (Chantix) for quitting smoking?
A 2014 RCT published in the New England Journal of Medicine (n=1,310) found varenicline outperformed cytisine at 12-month continuous abstinence (19.9% vs 8.4%), though cytisine still significantly exceeded placebo. Cytisine costs approximately $20–40 USD per treatment course compared to over $400 for varenicline, making it a critical option in low- and middle-income countries where it is widely approved.
What is the standard cytisine dosage for smoking cessation?
The approved regimen in Eastern European markets (sold as Tabex) involves a 25-day tapering schedule: 1.5 mg tablets taken 6 times daily (9 mg/day) for the first 3 days, reducing to 5 tablets daily through day 12, then further tapering to 1–2 tablets daily by day 25. Smoking cessation is targeted around day 5 of the protocol, coinciding with peak receptor occupancy and withdrawal blunting.
Is cytisine FDA-approved in the United States?
As of 2024, cytisine is not FDA-approved in the United States and is not commercially available as a prescription medication there. It has been approved for smoking cessation in several Eastern European countries since the 1960s and is marketed as Tabex in Bulgaria and neighboring nations. Clinical trials and regulatory submissions are ongoing, driven partly by its cost-effectiveness profile relative to existing approved therapies.
Can cytisine cause nausea, and how can it be minimized?
Yes, nausea is the most frequently reported adverse effect, affecting approximately 15–25% of users in controlled trials, and is dose-dependent due to peripheral nicotinic receptor activation in the gastrointestinal tract. Taking cytisine tablets with food and maintaining adequate hydration during the higher-dose early phase of the protocol can meaningfully reduce gastrointestinal side effects. Nausea typically subsides as the dose is tapered after day 3 of the standard 25-day regimen.
Where does cytisine come from naturally, and is it toxic?
Cytisine is a naturally occurring quinolizidine alkaloid found primarily in seeds and other parts of Laburnum anagyroides (golden chain tree), Cytisus scoparius (Scotch broom), and related Fabaceae family plants. In its isolated form at high doses it is toxic, with the lethal dose in animal models being relatively low (LD50 ~101 mg/kg in mice), and ingestion of laburnum seeds causes nicotinic poisoning in children. At the therapeutic doses used in smoking cessation (1.5 mg per tablet), the safety margin is well established across decades of clinical use in Eastern Europe.
What are the common side effects of cytisine beyond nausea?
Clinical trials report side effects including headache, dizziness, insomnia, and gastrointestinal disturbances occurring in 10–30% of users, though most are mild and transient. Cytisine's partial agonist activity at nicotinic receptors can cause vivid dreams or sleep disturbances in some patients. These adverse events are generally less severe than those associated with varenicline and typically decrease after the first 1–2 weeks of treatment.
How long does cytisine stay in the body, and does it accumulate with repeated dosing?
Cytisine has a half-life of approximately 4.8 hours, meaning it is largely eliminated within 24 hours without significant accumulation over the standard 25-day treatment course. Its relatively short half-life necessitates multiple daily doses (typically 3–6 per day during the titration and maintenance phases) to maintain therapeutic receptor occupancy. This pharmacokinetic profile differs from varenicline, which has a much longer half-life enabling once-daily dosing.
Is cytisine effective for reducing cravings if someone relapses or restarts smoking cessation treatment?
Limited evidence suggests cytisine can be effective in repeat treatment attempts, though relapse rates are highest in the first 3–6 months post-treatment. Studies show that individuals who use cytisine and relapse can re-enter treatment with comparable efficacy to first-time users, making it a viable option for multiple quit attempts. However, long-term outcomes and optimal re-treatment timing remain understudied compared to single-course efficacy data.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w cytisine curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
